Table 1.
Clinic characteristics of anti-NMDAR encephalitis patients and controls.
| Anti-NMDAR Encephalitis (n = 23) | Control (n = 17) | p value | |
|---|---|---|---|
| Gender (male/female) | 8/15 | 8/9 | 0.000 |
| Age (years, mean ± SD) | 29.6±14.2 | 27.5±9.9 | 0.208 |
| Clinic symptoms (n, %) | |||
| Fever | 1 (4.4) | 0 | “- |
| Psychiatric symptom | 19 (82.6) | 0 | “- |
| Disorders of memory | 2 (8.7) | 0 | “- |
| Seizure | 12 (52.2) | 0 | “- |
| Abnormal movements | 1 (4.4) | 0 | “- |
| Automatic instability | 3 (13.1) | 0 | “- |
| Hypoventilation | 0 (0) | 0 | “- |
| CSF routine (mean ± SD) | |||
| WBC (×10E6/L) | 7.8±25.7 | 2.0±2.2 | 0.000 |
| GLU (mmol/l) | 3.7±0.6 | 3.7±0.6 | 0.924 |
| Cl (mmol/L) | 116.5±6.5 | 125±3.4 | 0.000 |
| Treatment (n, %) | |||
| Plasma exchange | 5 (21.7) | “- | “- |
| IVIg | 16 (69.6) | “- | “- |
| Steroids | 18 (78.3) | “- | “- |
| Qalb (mean ± SD, damage %) | 6.4±3.8 (43.5) | 4.445±1.167 (11.8) | 0.001 |
| CSF anti-NMDAR antibody positive (n, %) | 23 (100) | 0 | “- |
| Tumor comorbidity (n, %) | 2 (8.7) | 0 | “- |
| Max mRS | |||
| 3 (n, %) | 8 (34.8) | “- | “- |
| 4 (n, %) | 10 (43.5) | “- | “- |
| 5 (n, %) | 5 (21.7) | “- | “- |